Associated Genetic Biomarkers
EZH2 Y641S serves as an inclusion eligibility criterion in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains EZH2 Y641S as an inclusion criterion, 1 is phase 1 (0 open).
Trials with EZH2 Y641S in the inclusion eligibility criteria most commonly target diffuse large B-cell lymphoma, follicular lymphoma, and multiple myeloma .
Gsk2816126 is the most frequent therapy in trials with EZH2 Y641S as an inclusion criteria .
Significance of EZH2 Y641S in Diseases
Diffuse Large B-Cell Lymphoma +
EZH2 is altered in 9.48% of diffuse large B-cell lymphoma patients .
EZH2 Y641S is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 Y641S and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) .
Follicular Lymphoma +
Multiple Myeloma +
EZH2 Y641S is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 Y641S and multiple myeloma as inclusion criteria, 1 is phase 1 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.